Mersana Therapeutics (MRSN) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St indexes climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Strategy stock jumps 7% as firm shifts to active capital management
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
November 7, 2023 7:02 AM ESTAdvancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersanas B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersanas HER2 Immunosynthen ADCCapital resources expected to support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of... More
